Russia to start mass production of Scalpel loitering munition
The Scalpel is a loitering munition with a cross-wing design similar in appearance to the Lancet-3. (Photo: Vostok Design Bureau)
Russia’s Vostok Design Bureau will begin mass production of its Scalpel loitering munition in October this year and the type will be deployed to Russia’s Northern Military District, according to an article published by TASS on 7 September.
The Scalpel is a loitering munition with a cross-wing design similar in appearance to the established Lancet-3 from Zala Aero. It is currently undergoing flight tests and is expected to be deployed to Ukraine this year. It has been designed in ‘constant dialogue with operators’, TASS cited Vostok as saying.
Scalpel is described as a multipurpose loitering munition with internal warhead dimensions
Our news & analysis is now part of Defence Insight®
A Basic-level or higher Defence Insight subscription is now required to view this content.
More from Air Warfare
-
How India’s FCAS ambitions could reshape its combat-air roadmap
Participation in the French-led programme could provide India with access to sixth-generation technologies but force difficult choices over AMCA, TEDBF and indigenous propulsion development.
-
Pentagon’s 800% PAC-3 MSE surge faces production bottleneck as Patriot demand soars
The Pentagon wants to procure 3,203 PAC-3 MSE interceptors in FY2027, but production constraints and international demand could impact efforts to rebuild depleted missile stocks.
-
Canada targets 2028 operational debut for AIM-9X and AIM-120D missiles
The missile programmes form part of a broader effort to strengthen Canadian air-combat readiness as the RCAF transitions from the CF-188 to the F-35A and rebuilds its operational weapons stocks.
-
AIM-260 JATM deal puts Australia’s missile-industrial ambitions in focus
While a potentially accelerated acquisition timeline could strengthen the RAAF’s long-range air combat capability, Canberra’s continued reliance on US missile production is also put under the spotlight in parallel to its push to build a sovereign industry.